Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.325 billion-$4.525 billion to $4.325 billion-$4.525 billion vs $4.472 billion estimate.
Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.325 billion-$4.525 billion to $4.325 billion-$4.525 billion vs $4.472 billion estimate.